secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2026-09-30T20:08:28+00:00
Accession:  0001193125-26-409052
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 4.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Benitec engages Ernst & Young as auditor for fiscal year ending June 30, 2027
-----------------------------------------------------------------------------

- EY completed its client acceptance process on September 28, 2026, and executed the engagement letter with Benitec on September 29, 2026.
- The EY engagement covers the fiscal year ending June 30, 2027; the approval was previously disclosed in a Form 8-K filed September 24, 2026.
- Filing is an Item 4.01 change-in-certifying-accountant notice; no resignation, disagreement, or restatement disclosure is provided.
- Signed by Chief Executive Officer Dr. Jerel A. Banks, dated September 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526409052/0001193125-26-409052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526409052/bntc-20260929.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-409052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer